Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals

J Med Chem. 2009 Jan 8;52(1):10-3. doi: 10.1021/jm801294h.

Abstract

The potency of second generation antisense oligonucleotides (ASOs) in animals was increased 3- to 5 -fold (ED(50) approximately 2-5 mg/kg) without producing hepatotoxicity, by reducing ASO length (20-mer to 14-mer) and by employing novel nucleoside modifications that combine structural elements of 2'-O-methoxyethyl residues and locked nucleic acid. The ability to achieve this level of potency without any formulation agents is remarkable and likely to have a significant impact on the future design of ASOs as therapeutic agents.

MeSH terms

  • Animals
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Expression Regulation, Enzymologic / genetics
  • Liver / drug effects
  • Liver / enzymology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Molecular Structure
  • Nucleic Acid Conformation*
  • Nucleosides / chemistry*
  • Oligonucleotides, Antisense / chemistry*
  • Oligonucleotides, Antisense / toxicity*
  • PTEN Phosphohydrolase / genetics
  • RNA, Messenger / drug effects
  • Toxicity Tests

Substances

  • Nucleosides
  • Oligonucleotides, Antisense
  • RNA, Messenger
  • PTEN Phosphohydrolase